Tamoxifen induces hypercoagulation and alterations in ERα and ERβ dependent on breast cancer sub‑phenotype ex vivo
Date
2020-11-06
Authors
Pather, Kyrtania
Augustine, T. N.
Journal Title
Journal ISSN
Volume Title
Publisher
Nature
Abstract
Tamoxifen shows efficacy in reducing breast cancer-related mortality but clinically, is associated
with increased risk for thromboembolic events. We aimed to determine whether breast tumour subphenotype
could predict propensity for thrombosis. We present two ex vivo Models of Tamoxifentherapy,
Model 1 in which treatment recapitulates accumulation within breast tissue, by treating
MCF7 and T47D cells directly prior to exposure to blood constituents; and Model 2 in which we
recreate circulating Tamoxifen by treating blood constituents prior to exposure to cancer cells. Blood
constituents included whole blood, platelet-rich plasma and platelet-poor plasma. Hypercoagulation
was assessed as a function of thrombin activity, expression of CD62P and CD63 activation markers
defined as an index of platelet activation, and platelet morphology; while oestrogen receptor
expression was assessed using immunocytochemistry with quantitative analysis. We determined,
in concert with clinical studies and contrary to selected laboratory investigations, that Tamoxifen
induces hypercoagulation, dependent on sub-phenotypes, with the T47D cell line capacity most
enhanced. We determined a weak positive correlation between oestrogen receptor expression, and
CD62P and CD63; indicating an association between tumour invasion profiles and hypercoagulation,
however, other yet unknown factors may play a predictive role in defining hypercoagulation.
Description
School of Anatomical Sciences, Faculty of Health Sciences, University of the Witwatersrand,
Johannesburg 2193, South Africa
Keywords
Citation
Pather K, Augustine TN. Tamoxifen induces hypercoagulation and alterations in erα and erβ dependent on breast cancer sub-phenotype ex vivo. Scientific Reports. 2020;10(1):19256. DOI: 10.1038/s41598-020-75779-y.